{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:36:11Z","timestamp":1787016971189,"version":"build-2736575974"},"reference-count":72,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FU356\/12-1"],"award-info":[{"award-number":["FU356\/12-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Projektnummer 422744262 \u2013 TRR 289"],"award-info":[{"award-number":["Projektnummer 422744262 \u2013 TRR 289"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010068","name":"Faculty of Medicine, University of Duisburg-Essen","doi-asserted-by":"crossref","award":["UMEA"],"award-info":[{"award-number":["UMEA"]}],"id":[{"id":"10.13039\/501100010068","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,5,27]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Migraine is the most common neurological disorder and one of the major causes of years lived with disability. Its treatment (especially of chronic forms) is often challenging and accompanied with adverse effects. Although new therapeutic approaches have recently emerged (eg, calcitonin gene-related peptide antibodies), these are linked to strict prescribing guidelines and therefore limited to only a minority of patients. Recently, randomised controlled trials have demonstrated that open-label placebo treatments can lead to significant and clinically relevant improvements of chronic pain conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This multicentre, randomised controlled clinical trial following a parallel group between-subject design aims to systematically investigate the impact of a 12-week open-label placebo treatment on moderate to severe headache days (primary outcome) in patients with episodic and chronic migraine in addition to treatment as usual. Secondary outcomes comprise the number of migraine days, pain intensity, intake of acute medication, quality of life, disability, global impression of change, tolerability and a responder rate. To systematically address potential predictors of placebo responses in patients with migraine, this study assesses potential psychometric predictors, salivary cortisol and alpha-amylase awakening responses, catechol-o-methyltransferase Val158Met polymorphisms, as well as functional and structural brain connectivity (ie, resting state functional MRI, diffusion tensor imaging). The data analysis will be performed on basis of the general linear model considering repeated measures (mixed model).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This protocol and all corresponding documents were approved with regard to their content and compliance with ethical regulations by the Ethics Committee of the Medical Faculty of the University Duisburg-Essen, Germany and the Ethics Committee of the Landes\u00e4rztekammer Hessen. The results from this study will be actively disseminated through manuscript publications and conference presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>German Clinical Trials Register (DRKS00021259).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-045969","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T11:41:02Z","timestamp":1624448462000},"page":"e045969","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of a 12-week open-label placebo treatment on headache days in episodic and chronic migraine: a study protocol for a parallel-group, multicentre, randomised controlled trial"],"prefix":"10.1136","volume":"11","author":[{"given":"Katharina","family":"Schmidt","sequence":"first","affiliation":[{"name":"Department of Neurology, Center for Translational Neuro- and Behavioral Sciences, University Medicine Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-0595","authenticated-orcid":false,"given":"Julian","family":"Kleine-Borgmann","sequence":"additional","affiliation":[{"name":"Department of Neurology, Center for Translational Neuro- and Behavioral Sciences, University Medicine Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagny","family":"Holle-Lee","sequence":"additional","affiliation":[{"name":"Department of Neurology, Center for Translational Neuro- and Behavioral Sciences, University Medicine Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly","family":"Gaul","sequence":"additional","affiliation":[{"name":"Migraine and Headache Clinic Koenigstein, K\u00f6nigstein im Taunus, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bingel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Center for Translational Neuro- and Behavioral Sciences, University Medicine Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"2025101812552648000_11.6.e045969.1","unstructured":"James SL , Abate D , Abate KH . Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017 2018."},{"key":"2025101812552648000_11.6.e045969.2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"2025101812552648000_11.6.e045969.3","first-page":"1","volume-title":"Headache classification Committee of the International headache Society (IHS) the International classification of headache disorders","volume":"38","author":"Olesen","year":"2018"},{"key":"2025101812552648000_11.6.e045969.4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03006.x"},{"key":"2025101812552648000_11.6.e045969.5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/14737175.2019.1621749","article-title":"Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies","volume":"19","author":"Negro","year":"2019","journal-title":"Expert Rev Neurother"},{"key":"2025101812552648000_11.6.e045969.6","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0333102418796842","article-title":"Cost-Effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives","volume":"38","author":"Sussman","year":"2018","journal-title":"Cephalalgia"},{"key":"2025101812552648000_11.6.e045969.7","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001683"},{"key":"2025101812552648000_11.6.e045969.8","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000700"},{"key":"2025101812552648000_11.6.e045969.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015591"},{"key":"2025101812552648000_11.6.e045969.10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2214.2007.00797.x","article-title":"Open-Label use of placebos in the treatment of ADHD: a pilot study","volume":"34","author":"Sandler","year":"2007","journal-title":"Child Care Health Dev"},{"key":"2025101812552648000_11.6.e045969.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20993-y"},{"key":"2025101812552648000_11.6.e045969.12","doi-asserted-by":"publisher","DOI":"10.1586\/ern.10.8"},{"key":"2025101812552648000_11.6.e045969.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04171.x"},{"key":"2025101812552648000_11.6.e045969.14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"2025101812552648000_11.6.e045969.15","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"2025101812552648000_11.6.e045969.16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006175"},{"key":"2025101812552648000_11.6.e045969.17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3923","article-title":"The placebo response in medicine: minimize","volume":"12","author":"Enck","year":"2013","journal-title":"maximize or personalize? Nat Rev Drug Discov"},{"key":"2025101812552648000_11.6.e045969.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2008.02.002"},{"key":"2025101812552648000_11.6.e045969.19","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2014.01079","article-title":"Prediction of placebo responses: a systematic review of the literature","volume":"5","author":"Horing","year":"2014","journal-title":"Front Psychol"},{"key":"2025101812552648000_11.6.e045969.20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048135"},{"key":"2025101812552648000_11.6.e045969.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2015.02.009"},{"key":"2025101812552648000_11.6.e045969.22","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.214"},{"key":"2025101812552648000_11.6.e045969.23","doi-asserted-by":"crossref","first-page":"285-e81","DOI":"10.1111\/j.1365-2982.2009.01440.x","article-title":"Serum correlates of the placebo effect in irritable bowel syndrome","volume":"22","author":"Kokkotou","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"2025101812552648000_11.6.e045969.24","doi-asserted-by":"crossref","first-page":"E2550","DOI":"10.1212\/WNL.0000000000007577","article-title":"Aberrant interactions of cortical networks in chronic migraine: a resting-state fMRI study","volume":"92","author":"Coppola","year":"2019","journal-title":"Neurology"},{"key":"2025101812552648000_11.6.e045969.25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a6cb32"},{"key":"2025101812552648000_11.6.e045969.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2012.07.010"},{"key":"2025101812552648000_11.6.e045969.27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hbm.24372","article-title":"White matter tract microstructure of the mPFC-amygdala predicts interindividual differences in placebo response related to treatment in migraine patients","volume":"40","author":"Liu","year":"2019","journal-title":"Hum Brain Mapp"},{"key":"2025101812552648000_11.6.e045969.28","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.23729"},{"key":"2025101812552648000_11.6.e045969.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2016.09.034"},{"key":"2025101812552648000_11.6.e045969.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0228-0"},{"key":"2025101812552648000_11.6.e045969.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2015.10.010"},{"key":"2025101812552648000_11.6.e045969.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)01008-4"},{"key":"2025101812552648000_11.6.e045969.33","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418758283"},{"key":"2025101812552648000_11.6.e045969.34","unstructured":"Diener HC , Gaul C , Kropp P . Therapie Der Migr\u00e4neattacke und Prophylaxe Der Migr\u00e4ne. Dtsch. Gesellschaft f\u00fcr Neurol, 2018. Available: https:\/\/www.dgn.org\/leitlinien\/3583-ll-030-057-2018-therapie-der-migraeneattacke-und-prophylaxe-der-migraene [Accessed 22 Feb 2021]."},{"key":"2025101812552648000_11.6.e045969.35","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(90)90068-O"},{"key":"2025101812552648000_11.6.e045969.36","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"2025101812552648000_11.6.e045969.37","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01214-2","article-title":"Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes","volume":"22","author":"Talbot","year":"2021","journal-title":"J Headache Pain"},{"key":"2025101812552648000_11.6.e045969.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00950.x"},{"key":"2025101812552648000_11.6.e045969.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.02.043"},{"key":"2025101812552648000_11.6.e045969.40","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2067"},{"key":"2025101812552648000_11.6.e045969.41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107665"},{"key":"2025101812552648000_11.6.e045969.42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036169","article-title":"Development of the generic, multidimensional treatment expectation questionnaire (TEX-Q) through systematic literature review, expert surveys and qualitative interviews","volume":"10","author":"Alberts","year":"2020","journal-title":"BMJ Open"},{"key":"2025101812552648000_11.6.e045969.43","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.2147\/JPR.S133032","article-title":"The fear of pain questionnaire-III and the fear of pain questionnaire-short form: a confirmatory factor analysis","volume":"10","author":"Vambheim","year":"2017","journal-title":"J Pain Res"},{"key":"2025101812552648000_11.6.e045969.44","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025570508954"},{"key":"2025101812552648000_11.6.e045969.45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10484-014-9245-x","article-title":"Individual and gender differences in subjective and objective indices of pain: gender, fear of pain, pain catastrophizing and cardiovascular reactivity","volume":"39","author":"Etherton","year":"2014","journal-title":"Appl Psychophysiol Biofeedback"},{"key":"2025101812552648000_11.6.e045969.46","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-013-0330-2"},{"key":"2025101812552648000_11.6.e045969.47","unstructured":"Wright CD , McNeil DW . Fear of pain across the adult life span. Pain Med."},{"key":"2025101812552648000_11.6.e045969.48","doi-asserted-by":"publisher","DOI":"10.1024\/\/0170-1789.22.3.216"},{"key":"2025101812552648000_11.6.e045969.49","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001682"},{"key":"2025101812552648000_11.6.e045969.50","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2007.34"},{"key":"2025101812552648000_11.6.e045969.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jrp.2006.02.001"},{"key":"2025101812552648000_11.6.e045969.52","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2010.0407"},{"key":"2025101812552648000_11.6.e045969.53","unstructured":"et al Laux L , Hock M , Bergner-K\u00f6ther R . STADI - Das State-Trait-Angst-Depressions-Inventar, 2013. Available: https:\/\/www.testzentrale.de\/shop\/das-state-trait-angst-depressions-inventar.html [Accessed 8 May 2020]."},{"key":"2025101812552648000_11.6.e045969.54","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-016-0875-9","article-title":"The German version of the Perceived Stress Scale - psychometric characteristics in a representative German community sample","volume":"16","author":"Klein","year":"2016","journal-title":"BMC Psychiatry"},{"key":"2025101812552648000_11.6.e045969.55","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-81502-2","article-title":"Effects of open-label placebos on test performance and psychological well-being in healthy medical students: a randomized controlled trial","volume":"11","author":"Kleine-Borgmann","year":"2021","journal-title":"Sci Rep"},{"key":"2025101812552648000_11.6.e045969.56","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(90)90004-A"},{"key":"2025101812552648000_11.6.e045969.57","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jpsychores.2015.10.010","article-title":"Is somatosensory amplification a risk factor for an increased report of side effects? reference data from the German general population","volume":"79","author":"Doering","year":"2015","journal-title":"J Psychosom Res"},{"key":"2025101812552648000_11.6.e045969.58","unstructured":"Rief W , Nestoriuc Y , Mueller E . Generic rating scale for previous treatment experiences, treatment expectations, and treatment effects (GEEE) [PREPRINT]. PsychArchives."},{"key":"2025101812552648000_11.6.e045969.59","doi-asserted-by":"crossref","unstructured":"Faul F , Erdfelder E , Lang AG . G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. In: Behavior Research Methods. Psychonomic Society Inc 2007:175\u201391.","DOI":"10.3758\/BF03193146"},{"key":"2025101812552648000_11.6.e045969.60","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-018-0235-4"},{"key":"2025101812552648000_11.6.e045969.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2011.09.015"},{"key":"2025101812552648000_11.6.e045969.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.116889"},{"key":"2025101812552648000_11.6.e045969.63","unstructured":"Crc 289 treatment expectation. Z02: what influences the treatment expectations of an individual patient? genes, hormones, stress? \/ TRR 289.. Available: https:\/\/treatment-expectation.de\/en\/projects-people\/research-projects\/z02 [Accessed 16 Mar 2021]."},{"key":"2025101812552648000_11.6.e045969.64","unstructured":"Crc 289 treatment expectation. Z03: can imaging techniques help to predict the effect of treatment expectations on therapeutic outcome? \/ TRR 289. Available: https:\/\/treatment-expectation.de\/en\/projects-people\/research-projects\/z03 [Accessed 16 Mar 2021]."},{"key":"2025101812552648000_11.6.e045969.65","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.18"},{"key":"2025101812552648000_11.6.e045969.66","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"2025101812552648000_11.6.e045969.67","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032868","article-title":"Open-Label placebo treatment of women with premenstrual syndrome: study protocol of a randomised controlled trial","volume":"10","author":"Frey Nascimento","year":"2020","journal-title":"BMJ Open"},{"key":"2025101812552648000_11.6.e045969.68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020262"},{"key":"2025101812552648000_11.6.e045969.69","doi-asserted-by":"crossref","unstructured":"Kaptchuk TJ , Friedlander E , Kelley JM . Placebos without deception: a randomized controlledtrial in irritable bowel syndrome. PLoS One : 2010.","DOI":"10.1371\/journal.pone.0015591"},{"key":"2025101812552648000_11.6.e045969.70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/jebm.12251","article-title":"Effects of placebos without deception compared with no treatment: a systematic review and meta-analysis","volume":"10","author":"Charlesworth","year":"2017","journal-title":"J Evid Based Med"},{"key":"2025101812552648000_11.6.e045969.71","doi-asserted-by":"publisher","DOI":"10.1353\/pbm.2018.0045"},{"key":"2025101812552648000_11.6.e045969.72","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3889"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-045969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:55:36Z","timestamp":1760817336000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-045969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":72,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,23]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/bmjopen-2020-045969"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-045969","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}